Use of cannabidiol in the treatment of epilepsy
OwnerGeoffrey GUY, Stephen WRIGHT +1inventors
InventorsGeoffrey GUY, Stephen WRIGHT, Orrin DEVINSKY
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to the use of cannabidiol (CBD) for the reduction of seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Lennox-Gastaut syndrome; Dravet syndrome; or Acardi syndrome.
Claims30
A method of reducing convulsive seizure frequency in a patient with a treatment-resistant epilepsy, which is Lennox-Gastaut syndrome, comprising administering to the patient in need thereof cannabidiol (CBD), wherein the CBD has a purity of at least 98% (w/w) CBD and comprises not more than 0.15% (w/w) Δ9-tetrahydrocannabinol (THC), wherein the dose of the CBD ranges from 5-25 mg/kg/day.
A method of treating seizures in a subject having Aicardi Syndrome, comprising administering to the subject in need thereof cannabidiol (CBD), wherein the CBD has a purity of at least 95 (w/w), and the dose of CBD ranges from about 5-25 mg/kg/day.
The method of claim 24, wherein the CBD is administered as a composition, comprising cannabidiol (CBD), a solvent, a co-solvent, a sweetener, and a flavoring.
Dependencies are inferred from the claim text.